Patents by Inventor Wulf Dirk LEUSCHNER

Wulf Dirk LEUSCHNER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11129905
    Abstract: Provided herein are bivalent, bispecific binding proteins that specifically bind to two different HIV-1 Env protein epitopes.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: September 28, 2021
    Assignee: SANOFI
    Inventors: Zhi-Yong Yang, Gary J. Nabel, Ling Xu, Jochen Beninga, Jochen Kruip, Ercole Rao, Wulf Dirk Leuschner, Christian Beil, Christian Lange
  • Publication number: 20210292423
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Application
    Filed: January 12, 2021
    Publication date: September 23, 2021
    Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
  • Publication number: 20210061925
    Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 4, 2021
    Inventors: Zhi-Yong YANG, Gary J. NABEL, Lan WU, Edward SEUNG, Ronnie WEI, Jochen BENINGA, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Carsten CORVEY
  • Patent number: 10906978
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: February 2, 2021
    Assignee: SANOFI
    Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
  • Patent number: 10882922
    Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: January 5, 2021
    Assignee: SANOFI
    Inventors: Zhi-Yong Yang, Gary J. Nabel, Lan Wu, Edward Seung, Ronnie Wei, Jochen Beninga, Ercole Rao, Wulf Dirk Leuschner, Christian Beil, Christian Lange, Carsten Corvey
  • Publication number: 20200262926
    Abstract: Binding proteins comprising a VL region paired with a VH region, and a CH1 region paired with a CL region, wherein the VL region and VH region comprise opposite charged mutations to facilitate pairing, and wherein the CH1 region and CL region comprise mutations to facilitate pairing, are provided. Binding proteins comprising one or more cysteine residues engineered into the VH/VL pair to form one or more disulfide bonds, are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.
    Type: Application
    Filed: December 23, 2019
    Publication date: August 20, 2020
    Inventors: Marta Amaral, Christian Beil, Ingo Focken, Gerhard Hessler, Soraya Hoelper, Jennifer Jung, Christian Lange, Wulf-Dirk Leuschner, Ercole Rao, Garima Tiwari, Sandra Weil
  • Publication number: 20200255540
    Abstract: Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.
    Type: Application
    Filed: December 23, 2019
    Publication date: August 13, 2020
    Inventors: Christian Beil, Karl-Christian Engel, Gerhard Hessler, Soraya Hoelper, Christian Lange, Thomas Langer, Cendrine Lemoine, Wulf-Dirk Leuschner, Sevim Oezguer Bruederle, Ercole Rao, Nadja Spindler, Sandra Weil
  • Publication number: 20200054765
    Abstract: Provided herein are compositions comprising trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.
    Type: Application
    Filed: October 21, 2019
    Publication date: February 20, 2020
    Inventors: Zhi-Yong YANG, Gary J. NABEL, Ling XU, Ronnie WEI, Huawei QIU, Jochen BENINGA, Jochen KRUIP, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Mark CONNORS, John R. MASCOLA, Richard A. KOUP, Jinghe HUANG, Nicole A. DORIA-ROSE, Tongqing ZHOU, Peter D. KWONG, Young Do KWON, Amarendra PEGU, Mangaiarkarasi ASOKAN
  • Publication number: 20190241657
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and CD123. The invention also relates to pharmaceutical compositions comprising said antibody-like binding protein and the use of said pharmaceutical compositions and antibody-like binding protein to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein.
    Type: Application
    Filed: July 17, 2017
    Publication date: August 8, 2019
    Applicant: SANOFI
    Inventors: Jana ALBRECHT, Christian BEIL, Jochen BENINGA, Katja KROLL, Christian LANGE, Wulf Dirk LEUSCHNER, Ercole RAO, Marion SCHNEIDER, Peter WONEROW, Stéphane GUERIF
  • Publication number: 20190054182
    Abstract: Provided herein are compositions comprising trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, where in a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.
    Type: Application
    Filed: October 24, 2016
    Publication date: February 21, 2019
    Applicants: Sanofi, The USA, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Zhi-Yong YANG, Gary J. NABEL, Ling XU, Ronnie WEI, Huawei QIU, Jochen BENINGA, Jochen KRUIP, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Mark CONNORS, John R. MASCOLA, Richard A. KOUP, Jinghe HUANG, Nicole A. DORIA-ROSE, Tongqing ZHOU, Peter D. KWONG, Young Do KWON, Amarendra PEGU, Mangaiarkarasi ASOKAN
  • Publication number: 20180222987
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
  • Publication number: 20180057567
    Abstract: Provided herein are multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies.
    Type: Application
    Filed: August 25, 2017
    Publication date: March 1, 2018
    Inventors: Ercole Rao, Christian Beil, Christian Lange, Katja Kroll, Wulf-Dirk Leuschner, Ingo Focken, Thomas Langer, Nadja Spindler
  • Publication number: 20180057597
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Application
    Filed: July 20, 2017
    Publication date: March 1, 2018
    Inventors: Jana ALBRECHT, Cédric BARRIERE, Christian BEIL, Jochen BENINGA, Chantal CARREZ, Stéphane GUERIF, Katja KROLL, Christian LANGE, Cendrine LEMOINE, Wulf-Dirk LEUSCHNER, Ercole RAO, Marion SCHNEIDER, Marie-Cécile WETZEL, Peter WONEROW
  • Publication number: 20170320967
    Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Application
    Filed: April 13, 2017
    Publication date: November 9, 2017
    Inventors: Zhi-Yong YANG, Gary J. NABEL, Lan WU, Edward SEUNG, Ronnie WEI, Jochen BENINGA, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Carsten CORVEY